Next Article in Journal
Sphingosine Prevents Rhinoviral Infections
Next Article in Special Issue
Are There General Features of How Immune Responses Are Regulated That Can Provide Clues to How Remitting/Relapsing Multiple Sclerosis May Be Treated?
Previous Article in Journal
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Previous Article in Special Issue
Uncovering Novel Extracellular Matrix Transcriptome Alterations in Lesions of Multiple Sclerosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 5
10.3390/ijms25052483
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS)

Int. J. Mol. Sci. 2024, 25(5), 2483; https://doi.org/10.3390/ijms25052483
by Seyed Siyawasch Justus Lattau 1, Lisa-Marie Borsch 1, Kristina auf dem Brinke 1, Christian Klose 2, Liza Vinhoven 3, Manuel Nietert 3 and Dirk Fitzner 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2024, 25(5), 2483; https://doi.org/10.3390/ijms25052483
Submission received: 16 January 2024 / Revised: 2 February 2024 / Accepted: 13 February 2024 / Published: 20 February 2024
(This article belongs to the Special Issue Insights in Multiple Sclerosis (MS) and Neuroimmunology)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The research focuses on Plasma Lipidomic Profiling by Mass Spectrometry in MS to draw the potential clinical contribution for disease monitoring or personalized medicine. However there are many junk or mass signals in Figure 2, figure 5 BC, and Figure 6 A, which must be improved and should be friendly to the reader.

2. You only divided into active, inactive MS and health control, but you did not provide the BMI information of enrolled cases, and their age distribution, which should be challenged, due to lipid profile may be changed by daily food contents, please provide these informations and discuss this part, you know obesity is a chronic inflammtory  status may influence your information.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

This is a very nice work trying to elucidate more the pathogenesis of multiple sclerosis. 

It is not clear to me if there could be any direct implication into clinical practice (I think no) and what would be the further direction of this research to make it more practical.

I see that there are some remarks about CSF but I would appreciate some more info - do you expect cholesterol to be the same in circulating blood and CSF? What do you you expect is the influence of blood brain barrier on lipid levels in these two compartments? Would it be not more informatory to start with CSF examination? 

Most studies in MS with cholestorol lowering agents did not show effect. Can you comment on it? (You mention only Alzheimer´s.) As brain is full of lipids, one need to know the relationship between lowering of blood lipids and well-being of CNS cells first. What is the relationship? Do we have enough information? (not to make more harm than benefit)

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Comments and Suggestions for Authors

The authors responded to all my questions with adequate knowledge and experience in the field.

Back to TopTop